Unicycive Drug Faces 6-Month Review After FDA Accepts Resubmission
Key Facts
Unicycive Therapeutics announced that the U.S. Food and Drug Administration had accepted the resubmission of its application for oxylanthanum carbonate, starting a 6-month review period from the resubmission date. The company said in its statement that the agency classified the resubmission as Class 2, which carries that regulatory review period. The application concerns a drug the company is developing to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis. The acceptance follows regulatory setbacks caused by manufacturing deficiencies at an outside supplier, according to the company's announcements on the application. The resubmitted package included data from a new manufacturing supplier, returning the drug application to review by the U.S. agency.
Unicycive announced on June 30, 2026, that it had received a complete response letter from the agency regarding the drug application. It said at the time that the letter cited the same manufacturing deficiencies at the outside supplier identified in an earlier letter in June 2025. According to the FDA's explanation, a complete response letter means that the application's review cycle has been completed and that the application is not ready for approval. In announcing the subsequent letter, the company said the agency "did not raise any concerns about the clinical efficacy or safety data." The company thus attributed the application's setback in that review cycle to the supplier's manufacturing dossier, while reiterating the agency's position on the clinical data submitted to support the drug.
In its resubmission announcement, the company said the dossier included chemistry, manufacturing and controls data for a new outside supplier manufacturing the drug product. These data were the manufacturing addition the company cited in the package submitted to the agency for renewed review of the application. It said the new supplier had produced the drug and completed product stability studies spanning 12 months. Those studies concern the product made by the new supplier and form part of the documents the company submitted through the resubmission process. The inclusion of the supplier's data and stability studies follows the complete response letters that Unicycive linked to deficiencies at its previous outside manufacturer.
Unicycive said the new supplier's facility was last inspected by the FDA in March 2024. It added that the inspection resulted in a classification of "No Action Indicated," according to its resubmission announcement. On supply arrangements, the company intends to retain the original supplier alongside the new supplier, according to the same announcement. It attributed this arrangement to its desire to provide an alternative within the supply chain rather than rely on a single manufacturer for the product. As for a pre-approval inspection of the new supplier during the current review, the company said it did not know whether the U.S. agency would decide to require one before ruling on the drug's approval.
The application for oxylanthanum carbonate is supported by data from 3 clinical studies, according to Unicycive's announcement of the complete response letter. The dossier also includes preclinical studies and manufacturing data, alongside the clinical component the company submitted to support the regulatory application. In describing the drug, the company says it uses proprietary nanoparticle technology as part of its development for patients with chronic kidney disease on dialysis. According to the company's description, the technology aims to reduce the number of tablets patients take per dose as well as the size of those tablets. Unicycive says reducing the number and size of tablets may help patients adhere to treatment, an effect the company attributes to the drug's design and technology.
On its finances, Unicycive reported in its second-quarter results that cash, cash equivalents and marketable securities totaled $61.4 million on June 30, 2026. The company described these figures as unaudited in its announcement of its financial position at the end of the period. In the same announcement, it said it expected its cash runway to extend into 2027, its estimate of how long it could fund operations. The target decision date for the drug application falls within the year cited in the company's cash runway estimate. According to Unicycive's statement on the acceptance of the resubmission, the FDA set March 25, 2027, as the target date for a decision under the Prescription Drug User Fee Act.